Mendus Logo

Mendus

Clinical-stage company developing immunotherapies to prevent tumor recurrence.

IMMU | ST

Overview

Corporate Details

ISIN(s):
SE0005003654 (+1 more)
LEI:
529900AFBGFR7ZB50J95
Country:
Sweden
Address:
Västra Trädgårdsgatan 15, 111 53 Stockholm

Description

Mendus is a clinical-stage company developing immunotherapies to improve long-term survival for cancer patients. The company's primary focus is on preventing tumor recurrence, a leading cause of cancer-related mortality. By leveraging its expertise in allogeneic dendritic cell biology, Mendus designs therapies that stimulate the immune system to build active and long-lasting immunity against residual cancer cells. This approach aims to change the course of cancer treatment by offering durable responses while preserving the patient's quality of life. The company's pipeline is centered on maintenance therapies for various forms of cancer.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2019-08-29 08:00
Immunicum AB (publ) Announces Positive Phase II MERECA Topline Results Includin…
English PDF 97.3 KB
2019-08-20 08:00 Swedish PDF 1.1 MB
2019-08-20 08:00 English PDF 1.1 MB
2019-07-01 16:11 English PDF 34.3 KB
2019-06-28 08:31
Immunicum AB (publ) tidigarelägger publiceringen av delårsrapporten för april –…
Swedish PDF 93.7 KB
2019-06-28 08:31
Immunicum AB (publ) Announces New Issuance Date for Interim Report April – June…
English PDF 92.9 KB
2019-04-25 13:01
Kommuniké från årsstämma i Immunicum AB (publ) den 25 april 2019
Swedish PDF 88.7 KB
2019-04-25 13:01
Report from the Annual General Meeting of Immunicum AB (publ) on April 25, 2019
English PDF 88.5 KB
2019-04-25 08:01 Swedish PDF 1.1 MB
2019-04-25 08:01 English PDF 1.1 MB
2019-04-04 08:31 Swedish PDF 9.5 MB
2019-04-04 08:31 English PDF 9.5 MB
2019-03-26 08:31
Notice of Annual General Meeting in Immunicum AB (publ)
English PDF 149.3 KB
2019-03-26 08:31
Kallelse till årsstämma i Immunicum AB (publ)
Swedish PDF 144.4 KB
2019-03-22 14:39 English PDF 35.3 KB

Automate Your Workflow. Get a real-time feed of all Mendus filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mendus

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mendus via our API.

Get Historical Data →

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.